Payment overview · 2025
General Payments
$485.11
33 reported records · 10 companies
Healthcare provider profile · identity verified
Jeffrey Nations, MD
Allopathic & Osteopathic Physicians|Family Medicine · EASLEY, SC · NPI 1811327851
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Nations, MD received $485.11 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $141.09 | 29.1% | 15 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $110.78 | 22.8% | 5 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $54.74 | 11.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.51 | 9.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.81 | 6.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.83 | 6.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.99 | 5.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.69 | 3.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.20 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.47 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $485.11 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $141.09 | 15 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $110.78 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.51 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.81 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.81 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.83 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.12 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $26.26 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 516 | 94 |
| Alprazolam | Alprazolam | 356 | 39 |
| Omeprazole | Omeprazole | 315 | 71 |
| Lisinopril | Lisinopril | 286 | 77 |
| Diazepam | Diazepam | 281 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 275 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 271 | 73 |
| Lorazepam | Lorazepam | 270 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 263 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 254 | 57 |
| Clonazepam | Clonazepam | 223 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 222 | 60 |
| Meloxicam | Meloxicam | 203 | 36 |
| Furosemide | Furosemide | 184 | 48 |
| Tramadol Hcl | Tramadol Hcl | 161 | 31 |
| Metformin Hcl | Metformin Hcl | 157 | 41 |
| Sertraline Hcl | Sertraline Hcl | 156 | 35 |
| Trazodone Hcl | Trazodone Hcl | 154 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 152 | 26 |
| Potassium Chloride | Potassium Chloride | 151 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 41 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 125 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 120 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 25 |
| Mirtazapine | Mirtazapine | 110 | 20 |
| Losartan Potassium | Losartan Potassium | 107 | 30 |
| Famotidine | Famotidine | 106 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 19 |
| Ondansetron Odt | Ondansetron | 97 | 26 |
| Promethazine Hcl | Promethazine Hcl | 97 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 15 |
| Amoxicillin | Amoxicillin | 91 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 22 |
| Pregabalin | Pregabalin | 83 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 74 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 14 |
| Prednisone | Prednisone | 64 | 21 |
| Simvastatin | Simvastatin | 64 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 63 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 16 |
| Glipizide | Glipizide | 62 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Cephalexin | Cephalexin | 59 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 59 | suppressed |
| Ibuprofen | Ibuprofen | 58 | 12 |
| Montelukast Sodium | Montelukast Sodium | 58 | 18 |
| Celecoxib | Celecoxib | 57 | suppressed |
| Fluconazole | Fluconazole | 56 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 12 |
| Atenolol | Atenolol | 54 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 12 |
| Sucralfate | Sucralfate | 50 | suppressed |
| Estradiol | Estradiol | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 11 |
| Eliquis | Apixaban | 45 | suppressed |
| Ozempic | Semaglutide | 45 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Allopurinol | Allopurinol | 42 | 14 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Nabumetone | Nabumetone | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 37 | 27 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Carisoprodol | Carisoprodol | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 34 | suppressed |
| Baclofen | Baclofen | 33 | 11 |
| Carvedilol | Carvedilol | 33 | 12 |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 22 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Testosterone | Testosterone | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $485.11 · 33 records | ABBVIE INC. | BREZTRI, CAPLYTA, CAPVAXIVE, GARDASIL 9, LYBALVI, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error